We provide cancer companion diagnostic testing of tissue and non-invasive monitoring of circulating tumor DNA (ctDNA). Exceptional sensitivity to 0.001%.
Today, we are thrilled to share the news that Palmetto GBA’s Molecular Diagnostic Services Program (MolDX) Program issued a positive coverage decision for the Pathlight MRD test.
Read more here https://t.co/sOnMMVab6Z
Exciting News! We're delighted to welcome Vicki Fish as our new SVP Strategic Marketing.
Vicki will oversee global marketing strategy, portfolio positioning, and commercialization initiatives. #TeamSAGA#MRD#Pathlight
Today is Research Appreciation Day – a time to celebrate the brilliant minds driving innovation, discovery, and progress at #TeamSAGA
Thank you for everything you do!
#ResearchAppreciationDay
We will be in Boston for the upcoming #LiquidBiopsy for #Precision#Oncology Summit East Coast, June 26 - 27.
Find out about #Pathlight™ our next-generation, tumor-informed multi-cancer molecular residual disease (#MRD) test.
Meet Our Incredible #TeamSAGA at #ASCO25.
Stop by our booth (#36150) to connect with the passionate minds behind our mission is to intercept cancer at the earliest stages when it’s most treatable.
We’re heading to #ASCO25!
Excited to connect, share, learn, and listen with the global oncology community.
Let’s talk innovation. Let’s talk MRD detection. Let’s shape the future of cancer care—together.
#ASCO2025#MRD#Oncology#CancerResearch#PrecisionMedicine
We are growing and looking for new team members to join our US based team. 🚀
- VP Medical Affairs - Remote US
- Medical Science Liaison – Southwest, US
- Controller - Morrisville, North Carolina
For a list of all our open roles > https://t.co/zohm65uYFa
Heading to #AACR25?
Our team will be there Peter Collins, Patrick Eimerman, Scott A. Shell and Jennifer Yen.
At SAGA, we are redefining the standard for MRD detection and driving a new era of oncology patient care.
Breaking barriers in clinical performance 🚀
Today at World CB & CDx Summit Europe 🗓️
Patrick Eimerman, VP BD amd Partnering will be presenting at 11.50 ⏰
‘Next-Gen MRD: Increasing Access to Ultrasensitive ctDNA Assessment for Biomarker Discovery, Development, and CDx Programs’
Hear the very latest from SAGA…
A great day at the World CB & CDx Summit Europe in London today!
Informative presentations and excellent networking 🚀
SAGA Diagnostics is revolutionizing the earlier detection of Molecular Residual Disease (MRD) to help inform personalized treatment.
Meet our team onsite…
We are excited to be at World CB & CDx Summit Europe in London this week 🚀
Peter Collins, CEO and Patrick Eimerman, VP BD and Partnering will be attending.
#diagnostics#MRD#oncology
We are excited to be an official partner for the upcoming #LiquidBiopsy for Precision Oncology Summit in San Diego, Feb 18-20.
Our VP Business Development and Partnering Patrick Eimerman will be attending.
On #WorldCancerDay we are #UnitedByUnique.
At SAGA we know that behind every sample we process is a unique human story - a unique story of sadness, grief, resilience and hope.
https://t.co/2CwikfJt1s
LBA1 #esmo22 today I will be discussing three lines of evidence supporting causative link between air pollution and lung cancer in the context of a Tumour promoting role independent of DNA mutagenesis pioneered by Allan Balmain @UCSF and Isaac Berenblum @CRUKresearch
Happy holidays from all of us at SAGA! We look forward to delivering exciting results for cancer patients in 2022!
Below is our holiday card with a favorite recipe of the season. #Swedish#lussekatter, which are twirled saffron buns - tasty warm, or lightly toasted and buttered!